[1]Hubert K A, Wellik D M. Hox genes in development and beyond[J]. Development, 2023, 150(1): dev192476.
[2]Economides K D, Zeltser L, Capecchi M R. Hoxb13 mutations cause overgrowth of caudal spinal cord and tail vertebrae[J]. Dev Biol, 2003, 256(2): 317-330.
[3]Shah N, Sukumar S. The Hox genes and their roles in oncogenesis[J]. Nat Rev Cancer, 2010, 10(5): 361-371.
[4]Koester S W, Lu V M, Basil G W. Letter: predictors of progression-free survival in patients with spinal intramedullary ependymoma: a multicenter retrospective study by the Neurospinal Society of Japan[J]. Neurosurgery, 2023, 93(5): e146-e147.
[5]Gilbert M R, Ruda R, Soffietti R. Ependymomas in adults[J]. Curr Neurol Neurosci Rep, 2010, 10(3): 240-247.
[6]Ellison D W, Aldape K D, Capper D, et al. cIMPACT-NOW update 7: advancing the molecular classification of ependymal tumors[J]. Brain pathology, 2020 Sep,30(5):863-866.
[7]Wei M K, Qin Z K, Kong D X, et al. Echiuran Hox genes provide new insights into the correspondence between Hox subcluster organization and collinearity pattern[J]. Proc Biol Sci, 2022, 289(1982): 20220705.
[8]Peraldi R, Kmita M. 40 years of the homeobox: mechanisms of Hox spatial-temporal collinearity in vertebrates[J]. Development, 2024, 151(16): dev202508.
[9]Aguilar-Camacho J M, Harry N D, Zakas C. Comparative Hox genes expression within the dimorphic annelid Streblospio benedicti reveals patterning variation during development[J]. Evodevo, 2024, 15(1): 12.
[10]Miller A, Dasen J S. Establishing and maintaining Hox profiles during spinal cord development[J]. Semin Cell Dev Biol, 2024, 152/153: 44-57.
[11]Hu X, Wang Y, Zhang X Y, et al. DNA methylation of HOX genes and its clinical implications in cancer[J]. Exp Mol Pathol, 2023, 134: 104871.
[12]Benetti N, Gouil Q, Tapia Del Fierro A, et al. Maternal SMCHD1 regulates Hox gene expression and patterning in the mouse embryo[J]. Nat Commun, 2022, 13(1): 4295.
[13]He J, Li L, Wang S X, et al. Abnormal methylation of HOXA11 promoter promotes tumor progression in testicular germ cell tumor[J]. Am J Transl Res, 2024, 16(5): 1660-1668.
[14]De Bessa Garcia S A, Araújo M, Pereira T, et al. HOX genes function in breast cancer development[J]. Biochim Biophys Acta Rev Cancer, 2020, 1873(2): 188358.
[15]Jambhekar A, Dhall A, Shi Y. Roles and regulation of histone methylation in animal development[J]. Nat Rev Mol Cell Biol, 2019, 20(10): 625-641.
[16]Hawkins R D, Hon G C, Lee L K, et al. Distinct epigenomic landscapes of pluripotent and lineage-committed human cells[J]. Cell Stem Cell, 2010, 6(5): 479-491.
[17]Quaas C E, Lin B C, Long D T. Transcription suppression is mediated by the HDAC1-Sin3 complex in Xenopus nucleoplasmic extract[J]. J Biol Chem, 2022, 298(11): 102578.
[18]Lee H, Machado C R L, Hammaker D, et al. Joint-specific regulation of homeobox D10 expression in rheumatoid arthritis fibroblast-like synoviocytes[J]. PLoS One, 2024, 19(6): e0304530.
[19]Ahmad F, Sudesh R, Ahmed A T, et al. The multifaceted functions of long non-coding RNA HOTAIR in neuropathologies and its potential as a prognostic marker and therapeutic biotarget[J]. Expert Rev Mol Med, 2024, 26: e11.
[20]Turetzek N, Pechmann M, Janssen R, et al. Hox genes in spiders: their significance for development and evolution[J]. Semin Cell Dev Biol, 2024, 152/153: 24-34.
[21]Lourdusamy A, Rahman R, Grundy R G. Expression alterations define unique molecular characteristics of spinal ependymomas[J]. Oncotarget, 2015, 6(23): 19780-19791.
[22]Taylor M D, Poppleton H, Fuller C, et al. Radial glia cells are candidate stem cells of ependymoma[J]. Cancer Cell, 2005, 8(4): 323-335.
[23]Kim K T, Lee C H, Chung C K, et al. Is NF2 a key player of the differentially expressed gene between spinal cord ependymoma and intracranial ependymoma?[J]. World Neurosurg, 2018, 118: e906-e917.
[24]Palm T, Figarella-Branger D, Chapon F, et al. Expression profiling of ependymomas unravels localization and tumor grade-specific tumorigenesis[J]. Cancer, 2009, 115(17): 3955-3968.
[25]Zheng H Y, Baranova K, Song J, et al. Overexpression of long noncoding RNA HOTAIR is a unique epigenetic characteristic of myxopapillary ependymoma[J]. J Neuropathol Exp Neurol, 2020, 79(11): 1193-1202.
[26]Gu S X, Gu W T, Shou J J, et al. The molecular feature of HOX gene family in the intramedullary spinal tumors[J]. Spine, 2017, 42(5): 291-297.
[27]Barton V N, Donson A M, Kleinschmidt-DeMasters B K, et al. Unique molecular characteristics of pediatric myxopapillary ependymoma[J]. Brain Pathol, 2010, 20(3): 560-570.
[28]Purkait S, Praeger S, Felsberg J, et al. Strong nuclear expression of HOXB13 is a reliable surrogate marker for DNA methylome profiling to distinguish myxopapillary ependymoma from spinal ependymoma[J]. Acta Neuropathol, 2025, 149(1): 29.
[29]Wang H, Zhang S, Rehman S K, et al. Clinicopathological features of myxopapillary ependymoma[J]. J Clin Neurosci, 2014, 21(4): 569-573.
[30]Bockmayr M, Harnisch K, Pohl L C, et al. Comprehensive profiling of myxopapillary ependymomas identifies a distinct molecular subtype with relapsing disease[J]. Neuro Oncol, 2022, 24(10): 1689-1699.
[31]Carpenter E M. Hox genes and spinal cord development[J]. Dev Neurosci, 2002, 24(1): 24-34.
[32]Niederreither K, McCaffery P, Dräger U C, et al. Res-tricted expression and retinoic acid-induced downregulation of the retinaldehyde dehydrogenase type 2 (RALDH-2) gene during mouse development[J]. Mech Dev, 1997, 62(1): 67-78.
[33]Neijts R, Amin S, Van Rooijen C, et al. Cdx is crucial for the timing mechanism driving colinear Hox activation and defines a trunk segment in the Hox cluster topology[J]. Dev Biol, 2017, 422(2): 146-154.
[34]Liu C, Xie Y X, Chen X Y, et al. BAF45D-binding to HOX genes was differentially targeted in H9-derived spinal cord neural stem cells[J]. Sci Rep, 2024, 14(1): 29.
[35]Schumann Y, Dottermusch M, Schweizer L, et al. Morphology-based molecular classification of spinal cord ependymomas using deep neural networks[J]. Brain Pathol, 2024, 34(5): e13239.
[36]Vazquez I E, Ducray F. The role of radiotherapy, chemotherapy, and targeted therapies in adult intramedullary spinal cord tumors[J]. Cancers, 2024, 16(16): 2781.
[37]Rudà R, Bruno F, Pellerino A, et al. Ependymoma: evaluation and management updates[J]. Curr Oncol Rep, 2022, 24(8): 985-993.
[38]Cerretti G, Pessina F, Franceschi E, et al. Spinal ependymoma in adults: from molecular advances to new treatment perspectives[J]. Front Oncol, 2023, 13: 1301179.
|